1. Home
  2. PLBY vs CALC Comparison

PLBY vs CALC Comparison

Compare PLBY & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.85

Market Cap

202.6M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$6.67

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
CALC
Founded
1953
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
202.6M
88.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PLBY
CALC
Price
$1.85
$6.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$3.00
$16.00
AVG Volume (30 Days)
1.3M
103.2K
Earning Date
11-12-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$119,510,000.00
N/A
Revenue This Year
$4.97
N/A
Revenue Next Year
$8.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$1.42
52 Week High
$2.53
$7.20

Technical Indicators

Market Signals
Indicator
PLBY
CALC
Relative Strength Index (RSI) 50.31 71.29
Support Level $1.81 $5.55
Resistance Level $1.94 $7.20
Average True Range (ATR) 0.13 0.69
MACD -0.02 0.07
Stochastic Oscillator 26.61 86.15

Price Performance

Historical Comparison
PLBY
CALC

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: